Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Beta: 0.1506 (As of Jun. 27, 2026)


STU:08HH Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
72 GF Score
Price €1.66
GF Value €2.17
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Beta?

Shanghai Fosun Pharmaceutical (Group) Co STU:08HH -2.38% 72 Beta is 0.1506 as of Jun. 27, 2026. GuruFocus rates STU:08HH with a GF Score™ of 72/100 and a GF Value™ of €2.17 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Shanghai Fosun Pharmaceutical (Group) Co's Beta is 0.1506.


Shanghai Fosun Pharmaceutical (Group) Co  (STU:08HH) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Shanghai Fosun Pharmaceutical (Group) Co Beta Related Terms


Shanghai Fosun Pharmaceutical (Group) Co Beta Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Beta Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 0.16 0.88 0.90 -0.05

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.83 0.62 -0.05 0.31

STU:08HH vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Beta distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Beta falls into.


STU:08HH
72GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.1506 mean?
Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) has a Beta of 0.1506 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Beta too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Beta is 0.1506. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Beta compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Beta of 0.1506 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Beta is 0.1506. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.17, compared to a current price of €1.66 — trading 23.5% below its estimated fair value. The current Beta is 0.1506. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH), the current Beta is 0.1506 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of €1.66 is trading 23.5% below its estimated GF Value™ of €2.17. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for STU:08HH:

  • Beta: 0.1506
  • GF Value™: €2.17 vs. price of €1.66 (23.5% below fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the STU:08HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
72GF Score

Get the complete analysis for STU:08HH

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66
Price
€2.17
GF Value